Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
481
-
482
-
483
-
484
-
485
-
486
Regions (α-helices, β-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of >0.03 nm in at least ≥50% of its residues.
Published 2014“…<p>Regions (α-helices, β-sheets, and loops) showing an average increase or decrease of RMSF in the MTs compared to the WT; RMSF of a particular structure is taken to be increased or decreased if there is an average change in RMSF of >0.03 nm in at least ≥50% of its residues.…”
-
487
-
488
Resveratrol Prevents Oxidative Stress-Induced Senescence and Proliferative Dysfunction by Activating the AMPK-FOXO3 Cascade in Cultured Primary Human Keratinocytes
Published 2015“…<div><p>The aging process is perceived as resulting from a combination of intrinsic factors such as changes in intracellular signaling and extrinsic factors, most notably environmental stressors. …”
-
489
-
490
-
491
-
492
-
493
-
494
-
495
-
496
-
497
-
498
-
499
-
500
Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”